Madrigal Pharmaceuticals, Inc. (MDGL): who owns it and who trades it
As of Nov 16, 2026, MDGL insiders reported 177 open-market sales worth $69.4M and 5 purchases worth $35M in the last 12 months, with 89% of the sale value made under pre-set 10b5-1 plans. The largest seller was Paul A Friedman (Director), with $26.7M. 4 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Madrigal Pharmaceuticals
From the latest filingsOverall: more selling than buying. Insiders and famous investors mostly sold. Funds was close to even.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns MDGL
413 funds and institutions reported MDGL shares worth $12.8B at the end of Q2 2026. Some shares are counted by more than one filer, or lent out and counted twice, so the total can pass 100%. The largest holder is Baker Bros. Advisors LP with 9.3%.
Funds and institutions (13F) about 100%Everyone else 0%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| Baker Bros. Advisors LP | 2.14M | 9.30% | $1.2B | +0% |
| Rtw Investments, LP | 1.99M | 8.65% | $1.1B | No change |
| Jupiter Topco LLC | 1.94M | 8.40% | $1B | – |
| Avoro Capital Advisors LLC | 1.83M | 7.95% | $984M | +1% |
| Paulson & Co. Inc. | 1.34M | 5.81% | $720M | -4% |
| BlackRock, Inc. | 1.20M | 5.21% | $645M | -23% |
| Vanguard Capital Management LLC | 835,668 | 3.62% | $449M | +1% |
| Wellington Management Group LLP | 825,714 | 3.58% | $443M | +19% |
| Vanguard Portfolio Management LLC | 781,731 | 3.39% | $420M | -7% |
| State Street Corp | 527,057 | 2.29% | $283M | -14% |
| Citadel Advisors LLC | 507,233 | 2.20% | $272M | +12% |
| UBS Group AG | 401,708 | 1.74% | $216M | +241% |
| Geode Capital Management, LLC | 374,880 | 1.63% | $201M | -18% |
| FMR LLC (Fidelity) | 356,201 | 1.54% | $191M | -30% |
| William Blair Investment Management, LLC | 324,123 | 1.41% | $174M | -5% |
| Invesco Ltd. | 301,435 | 1.31% | $162M | -9% |
| Armistice Capital, LLC | 288,000 | 1.25% | $155M | +9% |
| Lord, Abbett & Co. LLC | 281,500 | 1.22% | $151M | +16% |
| Assenagon Asset Management S.A. | 248,428 | 1.08% | $133M | +1449% |
| Goldman Sachs Group Inc | 246,280 | 1.07% | $132M | -11% |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, MDGL insiders reported $35M of open-market purchases and $69.4M of sales. 89% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Nov 6, 2026 | Baker Bros. Advisors Lp +5 | Director | Purchase | 60,400 | $383.01 | $23.1M | Form 4 |
| Nov 6, 2026 | Baker Bros. Advisors Lp +5 | Director | Purchase | 13,740 | $388.29 | $5.3M | Form 4 |
| Nov 6, 2026 | Baker Bros. Advisors Lp +5 | Director | Purchase | 2,000 | $396.61 | $793K | Form 4 |
| Nov 6, 2026 | Shannon T Kelley | General Counsel | Sale plan | 1,077 | $400.00 | $431K | Form 4 |
| Nov 4, 2026 | Baker Bros. Advisors Lp +5 | Director | Purchase | 5,586 | $366.99 | $2.1M | Form 4 |
| Nov 4, 2026 | Baker Bros. Advisors Lp +5 | Director | Purchase | 10,080 | $368.11 | $3.7M | Form 4 |
| Sep 11, 2026 | William John Sibold | CEO | Sale plan | 60 | $533.09 | $32K | Form 4 |
| Sep 11, 2026 | William John Sibold | CEO | Sale plan | 218 | $535.94 | $117K | Form 4 |
| Sep 11, 2026 | William John Sibold | CEO | Sale plan | 160 | $537.62 | $86K | Form 4 |
| Sep 11, 2026 | William John Sibold | CEO | Sale plan | 687 | $540.59 | $371K | Form 4 |
| Sep 11, 2026 | William John Sibold | CEO | Sale plan | 368 | $541.64 | $199K | Form 4 |
| Sep 11, 2026 | William John Sibold | CEO | Sale plan | 1,202 | $542.60 | $652K | Form 4 |
| Sep 11, 2026 | William John Sibold | CEO | Sale plan | 1,539 | $544.02 | $837K | Form 4 |
| Sep 11, 2026 | William John Sibold | CEO | Sale plan | 761 | $544.83 | $415K | Form 4 |
| Sep 11, 2026 | William John Sibold | CEO | Sale plan | 120 | $546.38 | $65.6K | Form 4 |
| Sep 11, 2026 | William John Sibold | CEO | Sale plan | 106 | $534.06 | $56.6K | Form 4 |
| Sep 9, 2026 | William John Sibold | CEO | Sale plan | 160 | $542.55 | $86.8K | Form 4 |
| Sep 9, 2026 | William John Sibold | CEO | Sale plan | 131 | $527.88 | $69.2K | Form 4 |
| Sep 9, 2026 | William John Sibold | CEO | Sale plan | 347 | $529.27 | $184K | Form 4 |
| Sep 9, 2026 | William John Sibold | CEO | Sale plan | 522 | $530.23 | $277K | Form 4 |
| Sep 9, 2026 | William John Sibold | CEO | Sale plan | 368 | $531.99 | $196K | Form 4 |
| Sep 9, 2026 | William John Sibold | CEO | Sale plan | 512 | $533.09 | $273K | Form 4 |
| Sep 9, 2026 | William John Sibold | CEO | Sale plan | 396 | $534.20 | $212K | Form 4 |
| Sep 9, 2026 | William John Sibold | CEO | Sale plan | 644 | $535.27 | $345K | Form 4 |
| Sep 9, 2026 | William John Sibold | CEO | Sale plan | 1,040 | $536.11 | $558K | Form 4 |
| Sep 9, 2026 | William John Sibold | CEO | Sale plan | 640 | $537.17 | $344K | Form 4 |
| Sep 9, 2026 | William John Sibold | CEO | Sale plan | 520 | $538.30 | $280K | Form 4 |
| Sep 9, 2026 | William John Sibold | CEO | Sale plan | 215 | $539.03 | $116K | Form 4 |
| Sep 9, 2026 | William John Sibold | CEO | Sale plan | 505 | $540.19 | $273K | Form 4 |
| Sep 9, 2026 | William John Sibold | CEO | Sale plan | 362 | $541.65 | $196K | Form 4 |
| Aug 17, 2026 | Shannon T Kelley | General Counsel | Sale | 664 | $514.97 | $342K | Form 4 |
| Jul 20, 2026 | William John Sibold | CEO | Sale | 545 | $544.71 | $297K | Form 4 |
| Jul 20, 2026 | William John Sibold | CEO | Sale | 280 | $555.05 | $155K | Form 4 |
| Jul 20, 2026 | William John Sibold | CEO | Sale | 1 | $550.72 | $551 | Form 4 |
| Jul 20, 2026 | William John Sibold | CEO | Sale | 153 | $550.01 | $84.2K | Form 4 |
| Jul 20, 2026 | William John Sibold | CEO | Sale | 47 | $548.87 | $25.8K | Form 4 |
| Jul 20, 2026 | William John Sibold | CEO | Sale | 680 | $547.70 | $372K | Form 4 |
| Jul 20, 2026 | William John Sibold | CEO | Sale | 269 | $547.08 | $147K | Form 4 |
| Jul 20, 2026 | William John Sibold | CEO | Sale | 275 | $545.71 | $150K | Form 4 |
| Jul 20, 2026 | William John Sibold | CEO | Sale | 110 | $543.79 | $59.8K | Form 4 |
| Jul 20, 2026 | William John Sibold | CEO | Sale | 140 | $542.75 | $76K | Form 4 |
| Jun 1, 2026 | David Soergel | Chief Medical Officer | Sale plan | 1,042 | $495.74 | $517K | Form 4 |
| May 22, 2026 | Richard S Levy | Director | Sale plan | 80 | $519.98 | $41.6K | Form 4 |
| May 22, 2026 | Richard S Levy | Director | Sale plan | 782 | $518.76 | $406K | Form 4 |
| May 22, 2026 | Richard S Levy | Director | Sale plan | 1,497 | $517.59 | $775K | Form 4 |
| May 22, 2026 | Richard S Levy | Director | Sale plan | 723 | $516.87 | $374K | Form 4 |
| May 22, 2026 | Richard S Levy | Director | Sale plan | 657 | $515.92 | $339K | Form 4 |
| May 22, 2026 | Richard S Levy | Director | Sale plan | 343 | $514.67 | $177K | Form 4 |
| May 22, 2026 | Richard S Levy | Director | Sale plan | 40 | $512.97 | $20.5K | Form 4 |
| May 22, 2026 | Richard S Levy | Director | Sale plan | 439 | $512.50 | $225K | Form 4 |
| May 22, 2026 | Richard S Levy | Director | Sale plan | 610 | $511.40 | $312K | Form 4 |
| May 22, 2026 | Richard S Levy | Director | Sale plan | 151 | $510.36 | $77.1K | Form 4 |
| May 22, 2026 | Richard S Levy | Director | Sale plan | 40 | $506.68 | $20.3K | Form 4 |
| May 22, 2026 | Richard S Levy | Director | Sale plan | 320 | $508.24 | $163K | Form 4 |
| May 18, 2026 | David Soergel | Chief Medical Officer | Sale | 844 | $515.90 | $435K | Form 4 |
| Mar 6, 2026 | Mardi Dier | CFO | Sale plan | 160 | $434.20 | $69.5K | Form 4 |
| Mar 6, 2026 | Mardi Dier | CFO | Sale plan | 80 | $435.32 | $34.8K | Form 4 |
| Mar 6, 2026 | Mardi Dier | CFO | Sale plan | 80 | $436.69 | $34.9K | Form 4 |
| Mar 6, 2026 | Mardi Dier | CFO | Sale plan | 40 | $437.65 | $17.5K | Form 4 |
| Mar 6, 2026 | Mardi Dier | CFO | Sale plan | 646 | $431.94 | $279K | Form 4 |
| Mar 6, 2026 | Mardi Dier | CFO | Sale plan | 40 | $425.08 | $17K | Form 4 |
| Mar 6, 2026 | Mardi Dier | CFO | Sale plan | 420 | $426.86 | $179K | Form 4 |
| Mar 6, 2026 | Mardi Dier | CFO | Sale plan | 80 | $427.85 | $34.2K | Form 4 |
| Mar 6, 2026 | Mardi Dier | CFO | Sale plan | 160 | $429.00 | $68.6K | Form 4 |
| Mar 6, 2026 | Mardi Dier | CFO | Sale plan | 40 | $429.58 | $17.2K | Form 4 |
| Mar 6, 2026 | Mardi Dier | CFO | Sale plan | 120 | $430.90 | $51.7K | Form 4 |
| Mar 6, 2026 | Mardi Dier | CFO | Sale plan | 116 | $432.56 | $50.2K | Form 4 |
| Mar 6, 2026 | William John Sibold | CEO | Sale | 1,663 | $431.94 | $718K | Form 4 |
| Mar 6, 2026 | Shannon T Kelley | General Counsel | Sale | 360 | $431.94 | $155K | Form 4 |
| Mar 6, 2026 | Carole Huntsman | Chief Commercial Officer | Sale | 419 | $431.94 | $181K | Form 4 |
| Mar 6, 2026 | Rebecca Taub | Director | Sale | 491 | $431.94 | $212K | Form 4 |
| Mar 2, 2026 | Mardi Dier | CFO | Sale | 1,183 | $427.21 | $505K | Form 4 |
| Jan 26, 2026 | Carole Huntsman | Chief Commercial Officer | Sale plan | 570 | $494.59 | $282K | Form 4 |
| Jan 26, 2026 | Carole Huntsman | Chief Commercial Officer | Sale plan | 340 | $492.42 | $167K | Form 4 |
| Jan 26, 2026 | William John Sibold | CEO | Sale | 1,577 | $492.42 | $777K | Form 4 |
| Jan 26, 2026 | Rebecca Taub | Director | Sale | 647 | $492.42 | $319K | Form 4 |
| Jan 20, 2026 | Shannon T Kelley | General Counsel | Sale plan | 429 | $501.40 | $215K | Form 4 |
| Jan 20, 2026 | Shannon T Kelley | General Counsel | Sale plan | 263 | $490.77 | $129K | Form 4 |
| Jan 20, 2026 | Rebecca Taub | Director | Sale | 2,238 | $490.77 | $1.1M | Form 4 |
| Jan 9, 2026 | Paul A Friedman | Director | Sale plan | 280 | $551.24 | $154K | Form 4 |
| Jan 9, 2026 | Paul A Friedman | Director | Sale plan | 2,450 | $517.86 | $1.3M | Form 4 |
| Jan 9, 2026 | Paul A Friedman | Director | Sale plan | 681 | $521.03 | $355K | Form 4 |
| Jan 9, 2026 | Paul A Friedman | Director | Sale plan | 840 | $521.98 | $438K | Form 4 |
| Jan 9, 2026 | Paul A Friedman | Director | Sale plan | 970 | $523.00 | $507K | Form 4 |
| Jan 9, 2026 | Paul A Friedman | Director | Sale plan | 1,199 | $524.10 | $628K | Form 4 |
| Jan 9, 2026 | Paul A Friedman | Director | Sale plan | 2,432 | $525.05 | $1.3M | Form 4 |
| Jan 9, 2026 | Paul A Friedman | Director | Sale plan | 1,066 | $526.00 | $561K | Form 4 |
| Jan 9, 2026 | Paul A Friedman | Director | Sale plan | 1,560 | $526.97 | $822K | Form 4 |
| Jan 9, 2026 | Paul A Friedman | Director | Sale plan | 575 | $528.18 | $304K | Form 4 |
| Jan 9, 2026 | Paul A Friedman | Director | Sale plan | 691 | $529.17 | $366K | Form 4 |
| Jan 9, 2026 | Paul A Friedman | Director | Sale plan | 166 | $529.76 | $87.9K | Form 4 |
| Jan 9, 2026 | Paul A Friedman | Director | Sale plan | 280 | $530.69 | $149K | Form 4 |
| Jan 9, 2026 | Paul A Friedman | Director | Sale plan | 80 | $532.50 | $42.6K | Form 4 |
| Jan 9, 2026 | Paul A Friedman | Director | Sale plan | 332 | $534.16 | $177K | Form 4 |
| Jan 9, 2026 | Paul A Friedman | Director | Sale plan | 148 | $535.29 | $79.2K | Form 4 |
| Jan 9, 2026 | Paul A Friedman | Director | Sale plan | 473 | $536.02 | $254K | Form 4 |
| Jan 9, 2026 | Paul A Friedman | Director | Sale plan | 487 | $536.88 | $261K | Form 4 |
| Jan 9, 2026 | Paul A Friedman | Director | Sale plan | 80 | $537.85 | $43K | Form 4 |
| Jan 9, 2026 | Paul A Friedman | Director | Sale plan | 480 | $539.23 | $259K | Form 4 |
| Jan 9, 2026 | Paul A Friedman | Director | Sale plan | 600 | $540.36 | $324K | Form 4 |
Latest 100 of 182 trades in the last 12 months.
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Baker Bros. Advisors Lp | Director | $35M | – | Nov 6, 2026 |
| Paul A Friedman | Director | – | $26.7M | Jan 9, 2026 |
| Rebecca Taub | Director | – | $21.7M | Mar 6, 2026 |
| William John Sibold | President and CEO, Director | – | $10.5M | Sep 11, 2026 |
| Mardi Dier | EVP and CFO | – | $3.8M | Mar 6, 2026 |
| Richard S Levy | Director | – | $2.9M | May 22, 2026 |
| Carole Huntsman | Chief Commercial Officer | – | $1.7M | Mar 6, 2026 |
| Shannon T Kelley | General Counsel | – | $1.3M | Nov 6, 2026 |
| David Soergel | Chief Medical Officer | – | $952K | Jun 1, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
MDGL short interest
Moderate short interest. 9.2% of MDGL shares are sold short: about 1 share in 11. Over the last 12 reports the number of shares short went down 45%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 2.14M MDGL shares were sold short, 9.2% of the shares outstanding, down 2.6% from the report before. At the average daily volume of 279,558 shares, buying them all back would take about 7.6 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 2.14M | 9.20% | -3% | 279,558 | 7.6 |
| Oct 15, 2026 | 2.19M | 9.50% | -8% | 303,113 | 7.2 |
| Sep 30, 2026 | 2.40M | 10.37% | +6% | 245,001 | 9.8 |
| Sep 15, 2026 | 2.25M | 9.76% | +1% | 197,439 | 11.4 |
| Aug 31, 2026 | 2.24M | 9.70% | +11% | 236,743 | 9.5 |
| Aug 14, 2026 | 2.03M | 8.77% | +3% | 335,012 | 6.0 |
| Jul 31, 2026 | 1.97M | 8.51% | -5% | 406,250 | 4.8 |
| Jul 15, 2026 | 2.06M | 8.95% | -42% | 297,279 | 6.9 |
| Jun 30, 2026 | 3.53M | 15.30% | -7% | 568,813 | 6.2 |
| Jun 15, 2026 | 3.78M | 16.40% | -1% | 263,958 | 14.3 |
| May 29, 2026 | 3.82M | 16.58% | -2% | 271,574 | 14.1 |
| May 15, 2026 | 3.90M | 16.90% | +1% | 316,164 | 12.3 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Madrigal Pharmaceuticals company events
Madrigal Pharmaceuticals filed 9 reports on Form 8-K in the last 12 months, 4 of them about an important change (leadership). The latest was on Nov 3, 2026.
- Nov 3, 2026ResultsReleased financial results. Filing
- Aug 12, 2026LeadershipThe Board of Directors of Madrigal Pharmaceuticals, Inc. expanded the size of the Board from eight to nine members and, following the recommendation of its Nominating and Governance Committee, elected John C. Reed, M.D., Ph.D. to fill the newly created vacancy on the Board effective as of August… Filing
- Jul 30, 2026ResultsReleased financial results. Filing
- Jun 17, 2026LeadershipAt the annual meeting of stockholders of Madrigal Pharmaceuticals, Inc., the Company's stockholders approved the Madrigal Pharmaceuticals, Inc. 2026 Stock Plan, which was previously adopted by the Company's Board of Directors. Filing
- May 6, 2026ResultsReleased financial results. Filing
- Apr 28, 2026LeadershipThe Board of Directors of Madrigal Pharmaceuticals, Inc. completed a process to reclassify the membership of the Board’s three classes of directors to achieve a more equal apportionment of membership among the three classes following its Annual Meeting of Stockholders to be held on June 17, 2026. Filing
- Feb 19, 2026ResultsReleased financial results. Filing
- Jan 30, 2026AgreementMadrigal Pharmaceuticals, Inc., F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. (together, “Roche”) entered into the First Amendment to the Research, Development, and Commercialization Agreement dated as of December 18, 2008 between the Company and Roche. Filing
- Dec 11, 2025LeadershipThe Board of Directors of Madrigal Pharmaceuticals, Inc. appointed Rita Thakkar as Senior Vice President and Chief Accounting Officer of the Company, effective January 12, 2026. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Madrigal Pharmaceuticals financials
Famous investors that hold MDGL
4 of the 50 well-known investors we track reported holding MDGL in their latest 13F filing. The largest position is Ken Griffin's, worth $37.8M.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Ken Griffin · Citadel Advisors | Q3 2026 | 74,915 | $37.8M | 0.0% | -85% |
| Ray Dalio · Bridgewater Associates | Q3 2026 | 53,627 | $27M | 0.1% | New |
| Jim Simons · Renaissance Technologies | Q3 2026 | 44,222 | $22.3M | 0.0% | -4% |
| Israel Englander · Millennium Management | Q3 2026 | 8,295 | $4.2M | 0.0% | -90% |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 4 filings named MDGL in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Nov 16, 2026 | RTW Investments, LP | 13G/A | 1.4% |
| Nov 16, 2026 | RTW Investments, LP | 13G/A | 1.4% |
| Nov 6, 2026 | Baker Bros. Advisors LP | 13D/A | 10.0% |
| Nov 6, 2026 | Baker Bros. Advisors LP | 13D/A | 10.0% |
Questions about Madrigal Pharmaceuticals, Inc. (MDGL) stock
Who owns the most MDGL stock?
The largest reported owner of Madrigal Pharmaceuticals, Inc. (MDGL) is Baker Bros. Advisors LP, with 9.3% of the company. In total, 413 funds and institutions reported holding MDGL at the end of Q2 2026, together about 100% of the shares. See the largest owners.
Are MDGL insiders buying or selling?
In the last 12 months, MDGL insiders reported 5 open-market purchases worth $35M and 177 sales worth $69.4M. The latest trade was on Nov 6, 2026. See every trade.
What is the short interest in MDGL?
As of Oct 30, 2026, 2.14M MDGL shares were sold short, 9.2% of the shares outstanding, down 2.6% from the report before. At the average daily volume of 279,558 shares, buying them all back would take about 7.6 trading days (days to cover). See the history.
Which famous investors hold MDGL?
4 of the 50 well-known investors we track reported MDGL in their latest 13F filing, including Ken Griffin, Ray Dalio, Jim Simons. The largest position is worth $37.8M. See all holders.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.